Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

Home

/

IRIX

I

IRIDEX Corporation (IRIX)

NCM – Цена в реальном времени. Валюта: USD

1.04

-0.01 (-0.95%)

При закрытии: May 12, 2026, 4:00 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

IRIX - IRIDEX Corporation Последние новости | Finranks

Iridex to Report First Quarter 2026 Financial Results on May 19, 2026

Iridex to Report First Quarter 2026 Financial Results on May 19, 2026

MOUNTAIN VIEW, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the first quarter 2026 and provide a business update after the close of trading on May 19, 2026.

Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology

Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology

MOUNTAIN VIEW, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a new partnership with EyeProGPO, an ophthalmology-focused group purchasing organization serving ophthalmology practices, ambulatory surgery centers (ASC), and hospitals across the United States.

Iridex's Q4 Loss Narrows Year Over Year on Retina Sales Growth

Iridex's Q4 Loss Narrows Year Over Year on Retina Sales Growth

IRIX incurs narrower year-over-year loss per share in Q4 as growth in retina systems and glaucoma probes boosts revenues, though margins remain pressured by higher costs.

IRIDEX Corporation (IRIX) Q4 2025 Earnings Call Transcript

IRIDEX Corporation (IRIX) Q4 2025 Earnings Call Transcript

IRIDEX Corporation (IRIX) Q4 2025 Earnings Call Transcript

Iridex Reports Fourth Quarter and Full Year 2025 Financial Results

Iridex Reports Fourth Quarter and Full Year 2025 Financial Results

Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies

Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026

Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026

MOUNTAIN VIEW, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the fourth quarter and full year 2025 and provide a business update after the close of trading on March 26, 2026.

Iridex Announces Plans to Relocate Headquarters

Iridex Announces Plans to Relocate Headquarters

MOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its intent to relocate the Company's headquarters from Mountain View, California to San Jose, California.

Видео

No Data

There is no data to display

Пресс-релизы

Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology

Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology

MOUNTAIN VIEW, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a new partnership with EyeProGPO, an ophthalmology-focused group purchasing organization serving ophthalmology practices, ambulatory surgery centers (ASC), and hospitals across the United States.

Iridex Reports Fourth Quarter and Full Year 2025 Financial Results

Iridex Reports Fourth Quarter and Full Year 2025 Financial Results

Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies

Iridex Announces Plans to Relocate Headquarters

Iridex Announces Plans to Relocate Headquarters

MOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its intent to relocate the Company's headquarters from Mountain View, California to San Jose, California.

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025

MOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026.